Samumed, LLC

Biosplice Therapeutics, Inc.

Targegen, Inc.

Endeavor Biomedicines, Inc.

The Scripps Research Institute

Leland Stanford Junior University

Impact Biomedicines, Inc.

John Hood

Sunil Kumar Kc

David Mark Wallace

Jianguo Cao

Chandramouli Chiruta

Charlene F Barroga

Luis A Dellamary

Glenn Noronha

Chi Ching Mak

Venkataiah Bollu

Richard Soll

Sunil Kumar K C

Joel Renick

Ved Prakash Pathak

Andrew McPherson

Binqi Zeng

Yusuf Yazici

Christopher Swearingen

Joseph Timothy Marakovits

Osman Kibar

Wolfgang J Wrasidlo

David A Cheresh

Elena Dneprovskaia

Miguel De Los Rios

Ute Splittgerber

Anita Difrancesco

Xianchang Gong

Daniel L Lohse

Ningning Zhao

Brian Walter Eastman

Gopi Kumar Mittapalli

Mark David Bednarski

Brian Joseph Hofilena

Colleen Gritzen

Vishal Deshmukh

Kathy Barrett

Eric A Murphy

Catriona Jamieson

Ivor Royston

Eric Anthony Murphy

Anita J DiFrancesco

Martin A Schwartz

John Doukas

Tymara Berry

Paul A Frohna

William B Kiosses

Curtis L Scribner

Charlene Barroga

Andrew Mc Pherson

Richard M Soll

Ved Pathak

Daniel Lohse

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

Methods of improving lung function

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

Methods of treating fibrosis

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.

The present disclosure relates to &#x3b3;-diketone compounds, such as those having the structures: The disclosure also relates to cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for improving the aesthetic appearance of a subject's skin, for example, improving one or more of skin tone, radiance, clarity, tautness, skin firmness, plumpness, suppleness, softness, skin texture, skin texturization and moisturization, appearance of skin contours, appearance of hollow cheeks, appearance of sunken, baggy, or dark circles under eyes, skin luster, brightness, skin thickness, and skin elasticity and/or resiliency comprising application of the compounds or compositions disclosed.

Gamma-diketones for treatment and prevention of aging skin and wrinkles

Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Indazole-3-carboxamides and their use as Wnt/&#x3b2;-catenin signaling pathway inhibitors

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors

The present disclosure provides &#x3b3;-diketones or analogs thereof, that activate Wnt/&#x3b2;-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

&#x3b3;-diketones as Wnt/&#x3b2;-catenin signaling pathway activators

Indazole compounds for treating various diseases and pathologies are provided. More particularly, the use of an indazole compound or analogs thereof, in the treatment of inflammatory diseases or disorders is provided.

2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof

Method of treating fibrosis

Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.

Treatment of osteoarthritis

The present disclosure provides methods of mitigating thiamine deficiency.

Methods of treating myeloproliferative disorders

The present disclosure relates to compounds, cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.

Indazole-3-carboxamides and their use as WNT/B-catenin signaling pathway inhibitors

Gamma-diketones as wnt/&#x3b2;-catenin signaling pathway activators

Growing community of inventors

San Diego, CA, United States of America

John Hood